Questioning the economic evaluation of omalizumab.
Revicki
Dennis
D
Brown
Ruth
R
Dale
Peter
P
D018927:Anti-Asthmatic Agents / Q000191:economics* / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D006801:Humans; D018803:Models, Economic; D000069444:Omalizumab; D011788:Quality of Life
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab